A recent article published in Health Affairs, delves into the Federal Trade Commission’s (FTC) concerns regarding the inclusion of improper patents in the FDA’s Orange Book by pharmaceutical manufacturers. The…
The post Legislative Proposals to Tackle …
Legislative Proposals to Tackle Improper Pharmaceutical Patents in the Orange Book Read Post »
A recent article published in the Journal of Cheminformatics addresses the challenge of confirming the patent status of newly developed compounds, particularly in the pharmaceutical industry, where generating novel structures…
The post An AI Approach t…
An AI Approach to Generate Novel Pharmaceuticals using Patent Data Read Post »
A recent story by NPR echoes the findings of a collaboration between DrugPatentWatch and Bloomberg, which examined increasing competition between generic drug makers. The NPR article discusses the challenges in…
The post NPR on how low Drug Prices can …
The article “Settled: Patent characteristics and litigation outcomes in the pharmaceutical industry,” explores the relationship between Paragraph IV litigation characteristics and the probability of a Paragraph IV settlement in the…
The post Unveiling …
Unveiling the Secrets of Patent Litigation and Settlements in Pharmaceuticals Read Post »
In the ever-evolving landscape of the biotech and pharmaceutical sectors, accurate valuation of post-revenue drug assets stands as the linchpin for informed and strategic decision-making. The significance of this valuation…
The post Decoding Pfizer’s P…
Decoding Pfizer’s Portfolio: A New Model for Precision in Pharma Investments Read Post »
Researchers from West Virginia University College of Law have conducted a study examining the frequency of drug patent invalidations based on inequitable conduct. The findings, published in JAMA, shed light…
The post Navigating Legal Waters: Study Delv…
Navigating Legal Waters: Study Delves into Inequitable Conduct in Drug Patent Cases Read Post »
In a recent article in Pharmaceutical Executive, Alan Kalton, Senior Vice President of Commercial Strategy at Aktana, sheds light on the critical challenges facing pharmaceutical companies as they confront impending…
The post AI-Driven Strategies: Phar…
AI-Driven Strategies: Pharma’s Answer to Patent Expirations Read Post »
A paper titled “Analysis of Strategy for Extending Patent Protection of Rucaparib” by Zhifeng Wang. discusses the strategies employed by pharmaceutical companies to extend the patent protection period of the…
The post Maximizing Intellectual Property V…
Over the past two decades, Bayer Pharma has developed an in silico absorption, distribution, metabolism, and excretion (ADMET) platform with the aim of generating models for various pharmacokinetic and physicochemical…
The post Advancements in In Silic…
Over the past two decades, Bayer Pharma has developed an in silico absorption, distribution, metabolism, and excretion (ADMET) platform with the aim of generating models for various pharmacokinetic and physicochemical…
The post Advancements in In Silic…